Should you buy BeiGene stock now?
Yes, the technical signal for BeiGene is currently BUY. BeiGene trades at $327.87 as of 8/6/2026. The overall technical signal is: Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 7.731 with falling momentum (signal: 8.502); RSI is at 63.1 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $415.64 points to 26.8% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for BeiGene stock?
The average analyst price target for BeiGene is $415.64. The current price is $327.87, which gives an upside of 26.8%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $374.08 and $457.20.
Is BeiGene a dividend stock?
No, BeiGene does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of BeiGene stock?
BeiGene is rated as a stock with moderate risk. the annual standard deviation is 39.7%, which classifies the stock as moderate risk.
Is BeiGene overvalued?
No, BeiGene is considered undervalued based on the analyst price target (26.8% upside). BeiGene has the following valuation ratios: a P/E ratio of 73.1 (highly valued), a P/S ratio of 5.8, a P/B ratio of 6.9. The analyst price target suggests that the stock is undervalued by 26.8%.
Is BeiGene overbought?
No, BeiGene is not overbought. RSI is at 63.1 (neutral zone). The technical indicators show: RSI is at 63.1 (upper neutral zone), which shows positive momentum but is not yet overbought. In addition, the price is 3.4% above the 20-day average (short-term uptrend). In addition, MACD is positive, but momentum is falling.
When is the next BeiGene earnings report?
The date of the next earnings report for BeiGene has not been published yet. Check the company's investor calendar for updates.
Is BeiGene shorted?
Yes, BeiGene is shorted with 1.3% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying BeiGene stock?
No, insiders are not buying BeiGene shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 20 sales. On a net basis, 123,376,671 $ worth of shares were sold. Across the last 20 reported transactions, the split is 0 purchases and 20 sales, with a net 123,376,671 $ sold. Active sellers include Rosenberg Aaron, Lee Chan Henry, OYLER JOHN and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is BeiGene a good stock?
Based on our total score, BeiGene is rated as a mediocre stock with a total score of 42 out of 100. The stock scores around average on value, quality and momentum – it sits near the median in our database. The score is made up of Value: 18/100, Quality: 44/100, Momentum: 64/100. In addition: analysts see 26.8% upside to the price target; technical signal: Buy. Whether BeiGene is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for BeiGene stock?
The outlook for BeiGene based on current data: the average analyst price target is $415.64 (+26.8%); the stock is in an uptrend (above SMA50 and SMA200); the P/E ratio is 73.1 (high – the market expects growth). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is BeiGene stock rising?
BeiGene is rising right now. The technical indicators show: the price is 3.4% above the 20-day average; insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can BeiGene go?
The average analyst price target for BeiGene is $415.64, which corresponds to a potential gain of 26.8% from the current price of $327.87. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can BeiGene fall?
We lack enough history to give a specific floor for BeiGene. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does BeiGene do?
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyro... The company belongs to the Sundhed sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate BeiGene as an investment.
Did BeiGene raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from BeiGene. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is BeiGene making money or losing money?
Yes, BeiGene is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 8.9% — which is moderate. The operating margin (profit before interest and taxes) is 16.5%. At a P/E ratio of 73.1, you currently pay 73.1 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can BeiGene go bankrupt?
The bankruptcy risk of BeiGene is rated as moderate. Altman Z2 (a model for assessing financial distress) is 2.50 — that places the company in the middle zone. The Piotroski score (financial health 0-9, higher is better) is 5 — which is average. Debt relative to equity is 78% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does BeiGene have a lot of debt?
No, BeiGene has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 78%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector. Can BeiGene service its debt? Can service its debt without problems — the interest coverage ratio (how many times earnings can cover interest payments) is 8.9x, and the company has more cash than debt (net cash).
